A novel assay of thrombotic risk by unknown
ORAL PRESENTATION Open Access
A novel assay of thrombotic risk
Fahad Buskandar*, M Alobaidly, N Moran
From International Conference for Healthcare and Medical Students 2012
Dublin, Ireland. 2-3 November 2012
Introduction
It is widely believed that platelet responsiveness can be
used as a marker for assessing thrombotic risk in patients.
Therefore, there have been many attempts to develop sui-
table assays for quantifying platelet responses in clinical
samples 1. Platelet aggregometry is widely used, but is lim-
ited in its ability to assess platelet hyper-responsiveness. In
order to develop a better assay of thrombotic risk, we use
a novel assay to evaluate platelet secretion of adenosine
triphosphate & diphosphate (ATP/ADP) in response to
various agonists. This assay measures both the maximal
amount of adenine nucleotides released by a range of pla-
telet activators and the potency of each activator.
Methods
To determine the reproducibility of this assay, we assessed
4 healthy female subjects on 3 separate occasions. 10mls
of blood was drawn from subjects who had abstained from
medication for the previous 12 days. Platelet ATP/ADP
secretion was assessed in a 96 well assays as previously
described 2. Briefly, platelet secretion is assessed in
response to increasing doses of platelet agonists (Throm-
bin receptor activating peptide: TRAP 0.1-32µM; Collagen
related peptide: CRP 0.05-100µg/ml). Released ATP/ADP
is measured using firefly luciferase (Chronolume Corp).
Data are expressed as nmoles ATP/ADP secreted per 106
platelets. Dose-response curves are constructed and ana-
lysed using GraphPad Prism 5.0.
Results
The maximal amount of ATP/ADP released is similar for
both agonists tested (1.94±0.25 and 2.12±0.28 nmoles per
106 platelets in response to TRAP and CRP, respectively).
However, the potency of responses, measured as EC50
values, differed for the two agonists. For TRAP, the EC50
values were equivalent in all 4 donors (mean EC50 value is
4.84 ± 0.30µM; range 4.38-5.57µM). in response to CRP,
the potency of the responses were nearly similar for all the
donors (EC50 range from 0.37µg/ml to 1.08µg/ml). None-
theless, there is a high degree of concordance within all
samples from any one donor.
Conclusion
Our data demonstrate that individual donors display
unique response-parameters which may be used to
assess thrombotic risk. In addition, we can conclude
that the dose of agonist that causes a half-maximal
response is a reliable index of platelet responsiveness.
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